10:53 AM EDT, 06/05/2026 (MT Newswires) -- Charles River Laboratories ( CRL ) has the potential to outperform expectations in the second half of 2026, RBC Capital Markets analysts said in a Thursday note.

Analysts said that the company's "Pathways to Purpose" strategy is positioning it to capitalize on improving biotech funding and pharma investment in research and development.

RBC said that the company sees various opportunities, including in China, New Alternative Methods, and organic market share gains from a recent competitor's bankruptcy.

"We expect strong biopharma funding to continue in 2026 which combined with healthy cash runways should manifest in accelerated preclinical R&D spending growth in 2026 and into 2027," analysts said.

RBC has an outperform rating and a $215 price target on the stock.

Price: 184.94, Change: -0.85, Percent Change: -0.46